Pharma Stocks Outlook
Seen up on defensive bets, traders to buy on dips
This story was originally published at 22:18 IST on 29 May 2026
Register to read our real-time news.Informist, Friday, May 29, 2026
MUMBAI – Analysts expect pharmaceutical companies to see buying interest as the sector is shielded from the risk of inflationary pressures arising from the West Asia war hitting overall demand. While domestic-facing companies are expected to do well in the coming quarters, robust launch pipeline in the US is also seen aiding companies perform better, analysts said. Analysts also said the companies have performed significantly well in the March quarter. Technical analysts expect the Nifty Pharma index to buy on dips.
Analysts also said the pharmaceutical sector is a defensive bet amid the ongoing volatility in the market induced by the war. Since the West Asia war began, there has been significant inflows into the stocks in this sector, as indicated by the 6% rise in the Nifty Pharma against around a 7% fall in the Nifty 50. Sharp depreciation in rupee, alongside less risks from West Asia war to the small presence in the region makes the sector a safe bet, said Maitri Sheth, research analyst at Choice Institutional Equities. In the near term, this factor is to sustain, the analyst added.
For the week, shares of six companies that are part of the Nifty Pharma index closed higher. Wockhardt, Zydus Lifesciences, and Alkem Laboratories were the biggest gainers for the week. Ajanta Pharma and Ipca Laboratories were the underperformers. The Nifty Pharma Friday closed at 24345.80 points, down 370.20 points or 1.5%. For the next week, the index is expected to find support at 23750 points and face resistance at 25000 points, said Vipin Kumaar, assistant vice president - technical and fundamental research - Globe Capital Market. The bias is positive and the traders are expected to buy on dips, he added.
TOP HEADLINES
* Natco Pharma Jan-Mar consol PAT falls 34% YoY as sales down 39.5%
* Ipca Lab posts INR 2.62-billion PAT in Jan-Mar vs loss year ago
* Analyst Concall: GLP-1, semaglutide to drive Alkem Lab India sales in FY27
* Earnings Review: Alkem Labs Q4 PAT falls first time in 11 qtrs, misses view
* Graphite India posts INR-730-mln loss in Jan-Mar vs PAT year ago
* Lupin's cancer drug LNP8701 shows promise in early-stage trial
* Govt grants import, sale authorisation for Wockhardt's antibiotic Zaynich
* Zydus Life keeps buyback size unchanged, ups price to INR 1,260/share
* US FDA grants priority review to Zydus Life arm for saroglitazar drug
* Govt OKs Indian Medicines Pharma stake sale to Skymap Pharma for INR 1.2 bln
* Sun Pharma's UNLOXCYT gets 50% objective response rate in skin cancer trial
* AstraZeneca Pharma Jan-Mar PAT falls 23% YoY to INR 448.8 million
* Eli Lilly says gene editing therapy VERVE-102 cuts bad cholesterol up to 62%
* Entero Health Jan-Mar consol PAT rises 9% on year to INR 280 mln
* Blue Jet Healthcare Jan-Mar PAT falls 41.6% YoY as sales fall 31%
* US FDA issues four observations on Aurobindo Pharma arm's Telangana mfg unit
* Analyst Concall:Divi's Labs eyes double-digit sales growth, firm margin FY27
* Analyst Concall: Divi's Labs eye FY27 double-digit growth, margins steady
* Earnings Review:Divi's Lab revenue growth slowest in 2 yrs; Q4 PAT above view
* Glenmark Pharma US arm to pay $29.63 mln over 5 yrs to settle legal disputes
* Analyst Concall: Sun Pharma US generics ops hit by lack of FDA approvals
* IPO Alert: Cotec Healthcare gets SEBI approval for fresh issue, OFS
* Earnings Review: Torrent Pharma PAT dn, sales surge post JB Chem acquisition
* HC division bench upholds bar on Dabur selling oil similar to Emami Navratna
* Lupin gets Chinese regulator's nod for influenza drug Oseltamivir Phosphate
* Earnings Review: Sun Pharma Q4 PAT misses view as costs surge, US ops weaken
Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:
| Company | Price | Week-on-Week Change in % | Resistance | Support |
| Abbott India | 26,855.00 | (-)3.50 | 28,325.00 | 25,895.00 |
| Alkem Laboratories | 5,498.00 | 1.70 | 5,903.30 | 5,269.30 |
| Aurobindo Pharma | 1,426.40 | (-)2.50 | 1,472.70 | 1,387.90 |
| Biocon | 428.65 | (-)0.40 | 445.80 | 417.10 |
| Cipla | 1,401.00 | 0.10 | 1,450.80 | 1,357.80 |
| Divi's Laboratories | 6,667.00 | (-)3.20 | 6,961.00 | 6,443.00 |
| Dr Reddy's Laboratories | 1,303.50 | (-)0.30 | 1,341.00 | 1,278.80 |
| Gland Pharma | 2,250.00 | (-)3.60 | 2,380.00 | 2,165.00 |
| GlaxoSmithKline Pharmaceuticals | 2,210.20 | (-)4.20 | 2,296.50 | 2,151.30 |
| Glenmark Pharmaceuticals | 2,274.90 | 0.70 | 2,454.00 | 2,168.20 |
| Granules India | 773.85 | 2.90 | 818.00 | 746.50 |
| Ipca Laboratories | 1,524.40 | (-)4.90 | 1,677.80 | 1,406.20 |
| Laurus Labs | 1,362.00 | 1.40 | 1,407.60 | 1,333.60 |
| Lupin | 2,267.70 | (-)0.60 | 2,320.30 | 2,229.90 |
| Natco Pharma | 1,015.90 | (-)13.20 | 1,274.50 | 870.70 |
| Pfizer | 4,598.50 | (-)1.60 | 4,715.10 | 4,511.70 |
| Sanofi India | 3,097.10 | (-)2.10 | 3,329.70 | 2,937.70 |
| Sun Pharmaceutical Industries | 1,799.20 | (-)2.50 | 1,879.90 | 1,744.90 |
| Torrent Pharmaceuticals | 4,410.80 | (-)1.70 | 4,666.20 | 4,228.40 |
| Zydus Lifesciences | 1,077.70 | 3.70 | 1,132.40 | 1,043.80 |
| Index | Levels | |||
| Nifty Pharma | 24345.80 | (-)0.90 | 25230.10 | 23776.40 |
| Nifty 50 | 23547.75 | (-)0.70 | 24196.50 | 23160.40 |
| S&P Bse Sensex | 74775.74 | (-)0.90 | 76825.90 | 73564.00 |
End
Reported by Gopika Balasubramanium
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
